Sabbath guitarist done with chemo; radiation next
Black Sabbath guitarist and heavy metal legend Tony Iommi has updated his web site to let fans of the band know how he's doing with his treatment for non-Hodgkin's lymphoma. The entry, dated 27th March 2012, reads as follows:
Hiya:
A little update on how it's all going:
Well, I've had the last dose of chemotherapy so hopefully my body will start to get back to normal soon, the steroids were the worse. I've now got three weeks of radiotherapy coming up which I'm told can be very tiring so we'll see.
A big thanks to Ozzy and Geezer for coming over to England, it was a big incentive for me, we managed to work most days and have some great new tracks.
And, importantly thanks again for your kind messages, hope to be seeing you soon.
Tony
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
